Bullish Case: Johnson & Johnson is raising its full-year guidance due to surges in its pharmaceutical and medical devices businesses [CNBC]. Increased sales of drugs like Darzalex and Erleada, as well as their newly-structured business focusing on cancer treatments, contribute to this favorable picture [CNBC][The Street]. New developments like Nipocalimab and the QDOT MICRO Catheter, as well as the alleviation of supply constraints for Carvykti, also indicate potential future growth [][benzinga.com][medicaldevice-network.com].


Show historical bullish cases

Bearish Case: J&J's talc-related liabilities present a significant risk, with the company considering another bankruptcy filing and facing upcoming trials [Fortune][The Wall Street Journal]. Furthermore, the company faces criticism over the pricing of its tuberculosis treatment which may impact its reputation [kffhealthnews.org]. The impending loss of patent protection on the blockbuster drug Stelara also threatens J&J's revenues [CNBC].


Show historical bearish cases

Takeaway: Despite increasing revenues and promising developments in J&J's pharmaceutical division, major legal challenges and reputational threats related to their talc cases and drug pricing issues may undermine potential profits. Patent expiration creates further uncertainty around future revenue streams [CNBC][Fortune][kffhealthnews.org]. Investors should closely monitor these developments.


Show historical takeaways

Potential Outcomes:

1) Trials over the talc-relation cases: negative verdicts could lead to significant financial losses, while favourable outcomes may restore investors' confidence (~50%) [Fortune][The Wall Street Journal].

2) Patent expiration of Stelara: with the potential drop in revenues, this might force J&J to focus on new drug developments (~80%) [CNBC].

3) Nipocalimab passes clinical trials and enters market: this could boost J&J's income (~20%) [].

4) Settlement or win in the TB drug pricing case may enhance J&J's image (~30%) [kffhealthnews.org].


November 14, 2023







Correlated Stock Forecasts

Assets that tend to move strongly with JNJ



BAX Forecast + Options Trading Strategies   [BAX]  Baxter International (0.81)


JEPI Forecast + Options Trading Strategies   [JEPI]  JPMorgan Equity Premium Income (0.78)


ABT Forecast + Options Trading Strategies   [ABT]  Abbott Laboratories (0.72)


NIO Forecast + Options Trading Strategies   [NIO]  NIO (0.72)


SPHD Forecast + Options Trading Strategies   [SPHD]  Invesco S&P 500 High Dividend Low Vol (0.69)



Uncorrelated Stock Forecasts

Assets with little price relationship to JNJ



CFLT Forecast + Options Trading Strategies   [CFLT]  Confluent (-0.01)


SUM Forecast + Options Trading Strategies   [SUM]  Summit Materials (0.01)


LVS Forecast + Options Trading Strategies   [LVS]  Las Vegas Sands (-0.01)


NCNO Forecast + Options Trading Strategies   [NCNO]  Ncino (0.01)


IMGN Forecast + Options Trading Strategies   [IMGN]  Immunogen (0.01)



Anticorrelated Stock Forecasts

Assets that tend to move strongly against JNJ



TNP Forecast + Options Trading Strategies   [TNP]  Tsakos Energy Navigation (-0.52)


SPOT Forecast + Options Trading Strategies   [SPOT]  Spotify Technology (-0.53)


USAC Forecast + Options Trading Strategies   [USAC]  USA Compression (-0.56)


SGEN Forecast + Options Trading Strategies   [SGEN]  Seagen (-0.63)


PGR Forecast + Options Trading Strategies   [PGR]  Progressive (-0.66)